New cocktail aims to tackle tough lymphoma
NCT ID NCT07638787
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage trial tests whether adding sonrotoclax to standard Pola-R-CHP chemotherapy can improve outcomes for people with untreated large B-cell lymphoma that has high BCL2 expression or double-hit features. The study has two parts: first, finding a safe dose of sonrotoclax, then checking how well the combination works in 40 patients aged 18-75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sonrotoclax combined with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for aggressive large B-cell lymphoma with high BCL2 expression or double-hit genetics.
What could go wrong
This is an early Phase 1/2 trial with only 40 participants, so safety and effectiveness are not yet proven. The added drug may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••